Prosecution Insights
Prosecution Insights
33 pending office actions • 20 art units • 31 examiners • 0 of 33 (0%) have an AI response strategy ready • 30 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 19 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 19 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (3%) |
| §103 only | 13 (39%) |
| §102 only | 2 (6%) |
| §112 only | 3 (9%) |
| Double-patenting only | 5 (15%) |
| No statute on record | 9 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STIMPERT, PHILIP EARL | 2 | 63.0% | +49.2% |
| BOATENG, AFUA BAMFOAA | 2 | 46.3% | +71.4% |
| RUIZ, JOSHUA DAMIAN | 1 | 0.0% | +0.0% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 51.1% | +42.9% |
| LEE, SIN J | 1 | 68.9% | +25.4% |
| ROCHELLE, CIERRA MARIE | 1 | — | — |
| RODRIGUEZ, RAYNA B | 1 | 33.0% | +20.6% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.3% |
| SZNAIDMAN, MARCOS L | 1 | 37.1% | +15.7% |
| TRAN HO, LAM THUY VI | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18873142 | COLLABORATIVE FRAMEWORKS FOR IMPROVING REGULATORY DECISION-MAKING OF MEASUREMENT SOLUTIONS | RUIZ, JOSHUA DAMIAN | 30d overdue |
| 18002527 | SYSTEM AND METHOD FOR DETECTING OR PREDICTING RETURN IN MAJOR DEPRESSIVE DISORDER | KOLOSOWSKI-GAGER, KATHERINE | 20d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18298580 | Methods For Ensuring Resuspension Of Paliperidone Palmitate Formulations | STIMPERT, PHILIP EARL | 25d overdue |
| 18004464 | LONG-ACTING FORMULATIONS | BOATENG, AFUA BAMFOAA | 13d |
| 18954985 | METHOD OF TREATING DEPRESSION USING SELTOREXANT | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| 18833519 | NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE TO IMPROVE CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HRR ALTERATIONS | LEE, SIN J | — |
| 18429778 | Combination Therapy For Prostate Cancer | RODRIGUEZ, RAYNA B | — |
| 18566249 | PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES | SZNAIDMAN, MARCOS L | — |
| 18023622 | DRUG DELIVERY DEVICES WITH PROPELLANT | STIMPERT, PHILIP EARL | — |
| 18004336 | LONG-ACTING FORMULATIONS | BOATENG, AFUA BAMFOAA | — |
| Art Unit | Apps |
|---|---|
| 1627 | 4 |
| 1628 | 3 |
| 1675 | 3 |
| 3783 | 3 |
| 1647 | 2 |
| 1626 | 2 |
| 1623 | 2 |
| 1617 | 2 |
| 3684 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18873142 | COLLABORATIVE FRAMEWORKS FOR IMPROVING REGULATORY DECISION-MAKING OF MEASUREMENT SOLUTIONS | RUIZ, JOSHUA DAMIAN | 3684 | §103 | Final Rejection | 30d overdue | Pending | Dec 09, 2024 |
| 18954985 | METHOD OF TREATING DEPRESSION USING SELTOREXANT | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103 | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18833519 | NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE TO IMPROVE CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HRR ALTERATIONS | LEE, SIN J | 1613 | DP | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18693310 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | ROCHELLE, CIERRA MARIE | 1627 | — | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18429778 | Combination Therapy For Prostate Cancer | RODRIGUEZ, RAYNA B | 1628 | §103 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18528215 | RAPAMYCIN ANALOGS AND USES THEREOF | JARRELL, NOBLE E | 1699 | Other | Non-Final OA | 24d overdue | Pending | Dec 04, 2023 |
| 18566249 | PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES | SZNAIDMAN, MARCOS L | 1628 | DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18561347 | FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF ADVANCED SOLID TUMORS | TRAN HO, LAM THUY VI | 1647 | Other | Non-Final OA | 48d | Pending | Nov 16, 2023 |
| 18560242 | COMBINATION THERAPIES | MCINTOSH III, TRAVISS C | 1693 | Other | Non-Final OA | 9d | Pending | Nov 10, 2023 |
| 18557346 | MACROCYCLIC 2-ALLYLTETRAHYDROFURANS AS INHIBITORS OF MCL-1 | SHIM, DAVID M. | 1626 | §112 | Non-Final OA | 35d overdue | Pending | Oct 26, 2023 |
| 18548747 | 4-AMINO-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3 | CHICKS, ASHLI ARIANA | 1626 | §112 | Non-Final OA | 23d overdue | Pending | Sep 01, 2023 |
| 18546116 | MACROCYCLIC 1,3-BRIDGED 6-CHLORO-7-PYRAZOL-4-YL-1 H-INDOLE-2-CARBOXYLATE AND 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE DERIVATIVES AS MCL-1 INHIBITORS FOR THE TREATMENT OF CANCER | PECKHAM, RICHARD GRANT | 1627 | §112 | Non-Final OA | 25d overdue | Pending | Aug 11, 2023 |
| 18343689 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | WEIDNER, ADAM M | 1675 | Other | Non-Final OA | 17d overdue | Pending | Jun 28, 2023 |
| 18140344 | Suppression of Microglial Activation with Innate Lymphoid Cells | SAOUD, CHRISTINE J | 1646 | — | Non-Final OA | — | Pending | Apr 27, 2023 |
| 18298580 | Methods For Ensuring Resuspension Of Paliperidone Palmitate Formulations | STIMPERT, PHILIP EARL | 3783 | §103 | Final Rejection | 25d overdue | Pending | Apr 11, 2023 |
| 18044232 | FGFR INHIBITOR COMBINATION THERAPIES | VALLE, ERNESTO | 1623 | §103 | Final Rejection | 55d | Pending | Mar 07, 2023 |
| 18023637 | DRUG DELIVERY DEVICES WITH ON-BOARD DRUG DESTRUCTION | RUDDIE, ELLIOT S | 3785 | §103 | Final Rejection | — | Pending | Feb 27, 2023 |
| 18023622 | DRUG DELIVERY DEVICES WITH PROPELLANT | STIMPERT, PHILIP EARL | 3783 | §102 | Final Rejection | — | Pending | Feb 27, 2023 |
| 18022917 | DRUG DELIVERY DEVICES WITH A MECHANICAL STOP | DIOP, FATIMATA SAHRA | 3783 | §103 | Non-Final OA | — | Pending | Feb 23, 2023 |
| 18018741 | ANTAGONIST COMPOUNDS | MOU, LIYUAN | 1628 | DP | Final Rejection | — | Pending | Jan 30, 2023 |
| 18154020 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | ALLEN, MARIANNE P | 1647 | DP | Final Rejection | 181d overdue | Pending | Jan 12, 2023 |
| 18004464 | LONG-ACTING FORMULATIONS | BOATENG, AFUA BAMFOAA | 1617 | Other | Non-Final OA | 13d | Pending | Jan 06, 2023 |
| 18004336 | LONG-ACTING FORMULATIONS | BOATENG, AFUA BAMFOAA | 1617 | DP | Final Rejection | — | Pending | Jan 05, 2023 |
| 18002527 | SYSTEM AND METHOD FOR DETECTING OR PREDICTING RETURN IN MAJOR DEPRESSIVE DISORDER | KOLOSOWSKI-GAGER, KATHERINE | 3687 | §101 | Final Rejection | 20d | Pending | Dec 20, 2022 |
| 18084092 | BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer | HERNANDEZ, JACKSON J | 1627 | Other | Final Rejection | 14d | Pending | Dec 19, 2022 |
| 18076567 | CRYSTAL STRUCTURE OF BTK PROTEIN AND BINDING POCKETS THEREOF | SCHULTZHAUS, JANNA NICOLE | 1685 | §103 | Non-Final OA | 23d overdue | Pending | Dec 07, 2022 |
| 17998202 | TREATMENTS OF PROSTATE CANCER WITH COMBINATIONS OF ABIRATERONE ACETATE AND NIRAPARIB | IVANOVA, SVETLANA M | 1627 | §103 | Final Rejection | — | Pending | Nov 08, 2022 |
| 17997435 | METHODS OF IDENTIFYING MODULATORS OF THE IL-17 PATHWAY | EVANS, CHRISTOPHER RYAN | 1677 | §102 | Non-Final OA | — | Pending | Oct 28, 2022 |
| 17736305 | Formulations/Compositions Comprising a BTK Inhibitor | BORI, IBRAHIM D | 1629 | §103 | Final Rejection | 18d overdue | Pending | May 04, 2022 |
| 17616248 | NOVEL SPIROBICYCLIC INTERMEDIATES | MCMILLIAN, KARA RENITA | 1623 | §103 | Non-Final OA | 42d overdue | Pending | Dec 03, 2021 |
| 17509889 | Methods of Reducing Tau in Human Subjects | WANG, CHANG YU | 1675 | Other | Non-Final OA | 44d overdue | Pending | Oct 25, 2021 |
| 17598985 | FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF UROTHELIAL CARCINOMA | BRAUN, MADELINE E | 1624 | §103 | Non-Final OA | — | Pending | Sep 28, 2021 |
| 17477435 | METHODS FOR TREATING MULTIPLE MYELOMA | BENAVIDES, JENNIFER ANN | 1675 | §103 | Final Rejection | 4d overdue | Pending | Sep 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial